The First Quarterly Report 2022 of Huadong Medicine Co., Ltd.
Stock code: 000963 Stock abbreviation: Huadong Medicine Announcement No.: 2022-022
Huadong Medicine Co., Ltd.
The First Quarterly Report 2022
The Company and all members of the Board of Directors hereby guarantee that the information
presented in this report is authentic, accurate and complete and free of any false records,
misleading statements or material omissions.
Important Declaration:
1.The Board of Directors, Board of Supervisors, directors, supervisors and senior management of
Huadong Medicine Co., Ltd. (hereinafter referred to as the “Company”) hereby guarantee that the
information presented in this report is authentic, accurate and complete and free of any false records,
misleading statements or material omissions, and shall undertake individual and joint legal
liabilities.
2.The Company’s legal representative and the officer in charge of accounting, and head of
accounting department (accounting supervisor) hereby declare and guarantee that the financial
statements in this quarter report are authentic, accurate and complete.
3.Has the first quarterly report been audited?
□ Yes √ No
This report is prepared both in Chinese and English. Should there be any discrepancy between the
Chinese and English versions, the Chinese version shall prevail.
I. Key financial data
(I) Key Accounting Data and Financial Indicators
Whether the Company needs to perform retroactive adjustment or restatement of previous accounting data
□ Yes √ No
Change of the current
The current reporting period Same period last year reporting period over the
same period last year
Operating revenue (yuan) 8,932,579,251.75 8,896,632,277.36 0.40%
The First Quarterly Report 2022 of Huadong Medicine Co., Ltd.
Net profit attributable to shareholders of
704,364,775.13 758,380,756.56 -7.12%
listed companies (yuan)
Net profit attributable to shareholders of
listed companies after deducting 698,524,004.62 695,792,411.78 0.39%
non-recurring gains/losses (yuan)
Net cash flow from operating activities
(yuan) -260,603,628.32 302,314,164.48 -186.20%
Basic earnings per share (yuan/share) 0.4025 0.4334 -7.13%
Diluted earnings per share (yuan/share) 0.4025 0.4334 -7.13%
Weighted average return on equity (ROE) 4.17% 5.04% -0.87%
Change of the end of the
End of the current reporting
End of last year current reporting period
period
over the end of last year
Total assets (yuan) 28,436,893,634.69 26,996,403,366.69 5.34%
Net assets attributable to shareholders of
17,268,724,312.96 16,579,374,323.08 4.16%
listed companies (yuan)
(II)Items and amounts of non-recurring gains/losses
√Applicable □ N/A
Amount of the current
Item Note
reporting period
Gains/losses on disposal of non-current assets (including the
1,085,520.17
written-off part of the accrued assets impairment reserve)
Government grants included in current gains/losses(excluding
those closely related to normal operating activities, in line with
10,669,007.70
national policies and measured according to unified national
standards)
Other non-operating income or expenditure -5,011,007.02
Less: Amount affected by income tax 997,808.09
Amount affected by minority interest (after tax) -95,057.75
Total 5,840,770.51 --
Details of other gains/losses items satisfying the def
查看PDF原文
